Study Results Back Medtronic’s Next-Gen MiniMed 780G Pump for Type 1 Diabetes

Medtronic has released one-year data from its ADAPT study, the first multi-national, randomized controlled study comparing the performance of the MiniMed advanced hybrid closed-loop system (AHCL) against multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM).
 
The initial 6-month results, published in The Lancet Diabetes & Endocrinology, showed AHCL system users experienced a 27.6% absolute increase in Time in Range (TIR) and 1.4% reduction in HbA1C compared to those on MDI + isCGM without increased time in hypoglycemia. These results were greater overnight with a TIR increase of 30.2%. At the close of the six-month study period, all participants on MDI + isCGM crossed over to the MiniMed 780G system.
 
“These results further strengthen the case for us to move beyond the CGM-first paradigm to ensure patients experience these well-established clinical benefits of automated insulin delivery earlier at diagnosis,” Ohad Cohen, M.D., Senior Global Medical Affairs Director, Medtronic Diabetes, told the press. “The MiniMed 780G system is taking care of users in ways that individuals just aren’t able to with manual injections, even with the best of intentions, as there are so many variables that impact blood sugar levels on a daily basis.” 
 
Data from a second randomized controlled study sponsored by JDRF, called the CLVer Trial,  (n=113) showed that in youth (7 to17 years old) with newly-diagnosed type 1 diabetes, early intensive management, including use of an automated insulin delivery system, resulted in superior Time in Range of 78% compared to 64% Time in Range in the standard-care group (real-time CGM without automated insulin delivery) at one year. The CLVer Trial results were presented in a late-breaking clinical trial presentation at the ATTD Conference and concurrently published in the Journal of the American Medical Association(opens new window) (JAMA).
 
“There is a growing body of clinical evidence demonstrating the superiority of using automated insulin delivery systems as first-line treatment for type 1 diabetes rather than the standard stepwise approach of starting patients on a CGM first,” said Jennifer McVean, MD, Senior Medical Affairs Director, Medtronic Diabetes. “These results demonstrate patient success earlier in the course of their disease and across the age spectrum. Considering this compelling evidence, we’re committed to expanding access to our MiniMed 780G system so more people living with diabetes have an opportunity to improve short- and long-term health outcomes.”